Treatment of gastric cancer is stage specific and ranges from endoscopic resections in early gastric cancer to gastrectomy and multimodal treatment in locally advanced tumour situations. Palliative systemic treatment has the potential to prolong survival in advanced tumour stages. However, tumour-directed therapies and their side-effects potentially worsen the general condition of a patient.

Treatment discussions and decisions, especially when trading-off the options with the patient, have widened their focus from ‘technical’ terms like overall survival, disease-free survival and progression-free survival to patient reported outcomes (PROs) including quality of life (QoL). The assessment of PROs has evolved as important endpoint in clinical studies.

A precise definition of QoL seems impossible. Its multiple dimensions can be evaluated by various validated questionnaires like the QLQ-C30 and FACT-G focusing on different priorities. Special additional tools have been developed and validated to assess QoL in gastric cancer patients (QLQ-STO22, FACT-Ga).

We herein give an overview on the options to evaluate QoL in patients with gastric cancer and on published data on the impact of tumour-targeted therapy on QoL in these patients.

胃癌的治疗是特定阶段的，范围从早期胃癌的内窥镜切除术到局部晚期肿瘤情况的胃切除术和多式联运治疗。姑息性全身治疗有可能延长晚期肿瘤阶段的生存期。然而，肿瘤导向疗法及其副作用可能使患者的总体状况恶化。

治疗的讨论和决策，尤其是在与患者权衡取舍时，已将其关注点从“技术”术语扩展到了总体生存率，无病生存期和无进展生存期等患者报告的结局（PRO），包括生活质量（ QoL）。对PRO的评估已成为临床研究中的重要终点。

准确定义QoL似乎是不可能的。可以通过各种经过验证的问卷（如QLQ-C30和FACT-G）来评估其多个维度，重点放在不同的优先事项上。已经开发并验证了特殊的附加工具来评估胃癌患者的QoL（QLQ-STO22，FACT-Ga）。

我们在此概述胃癌患者评估QoL的选项，以及有关肿瘤靶向治疗对这些患者的QoL的影响的已公开数据。